Navigation Links
PLC Systems' RenalGuard to be Demonstrated at Cardiology Meetings in Germany and Israel
Date:4/13/2012

MILFORD, Mass., April 13, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that its innovative RenalGuard System™ is being demonstrated at two major cardiology meetings: Jahrestagung der DGK, the 78th Annual Congress of the German Society of Cardiology, April 11-14, 2012 in Mannheim, Germany, and the 59th Annual Conference of the Israel Heart Society, April 16-17, 2012 in Tel-Aviv, Israel.  Both ACIST Medical Systems, PLC's distributor in Germany, and A.M.I. Technologies, its distributor in Israel, are exhibiting RenalGuard in their booths at the events, demonstrating its ease of use along with scientific data supporting its efficacy to potential customers.  More than 8,000 clinicians and professionals are expected to attend the two conferences.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "These conferences are premier cardiovascular events in Germany and Israel, two major new markets for RenalGuard®.  RenalGuard is being displayed in both the ACIST and A.M.I. booths at these events, providing important exposure of our new technology to global knowledge leaders, and current and potential customers."

In March 2012, A.M.I. became the exclusive distributor of RenalGuard in Israel, and secured Ministry of Health approval to market and distribute RenalGuard in the country.  In October 2011, ACIST became the exclusive distributor of PLC's RenalGuard in Germany and France, the two largest countries in the European Union. 

About PLC Systems

PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.

Contact:  Mary T. Conway
508-520-2545
mconway@plcmed.com 


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Puritan Medical Products Company Launches New Diagnostic Collection and Transport Systems
2. Merit Medical Systems to Announce First Quarter 2012 Results on April 24, 2012
3. Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting
4. Psyche Systems Announces Availability of MicroPath, the First LIS for Microbiology
5. PLC Systems Reports Fourth Quarter and Full Year 2011 Results
6. Endo Announces Departure of American Medical Systems President
7. Frost & Sullivan: U.S. Nuclear Medicine and PET Imaging Systems Market Witnessed a Rebound in 2010, With PET Blazing the Trail
8. FDA Clears Expanded Compatibility for INOMAX® Drug-Delivery Systems
9. Psyche Systems Corporation and Aperio® Announce Availability of Their Fully Integrated Anatomic Pathology System
10. Argus Health Systems to Participate in NCPDP Focus Group
11. OxySure Systems Announces Supplier Agreement With Grainger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) today reported ... outlook and related key planning assumptions. Executive Summary ... percent increase compared to the prior year. ... compared to net income of $15 million in the fourth ... million compared to adjusted net income of $27 million in ...
(Date:2/27/2017)... 2017 Mederi Therapeutics today announced the ... 2468 patients who received  Stretta Therapy  to treat ... Systematic Review and Meta-Analysis of Controlled and Prospective ... of Gastroesophageal Reflux Disease ", was published in ... , MD, head of the Esophageal and Swallowing ...
(Date:2/27/2017)... --  Royal Philips (NYSE: PHG ... technology, today announced 510(k) clearance from the U.S. ... ElastQ Imaging capability, further expanding the functionalities of ... enables simultaneous imaging of tissue and assessment of ... of various liver conditions. With ElastQ Imaging, clinicians ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... ... staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution ... staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a ... , Previous studies have provided evidence of a link between pesticides and incidence ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist , ... office, Antoine Dental Center. Currently, patients can get single dental implants for $3,599 ... patients can learn more about these offers by contacting Antoine Dental Center. Both ...
(Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid ... explain why susceptibility to one of the disorders could place individuals at lower risk ... journal npj Schizophrenia. , “There is a wealth of genomic data on both ...
(Date:2/24/2017)... ... 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses ... not if you will be attacked, but when.” However, he and many others involved ... care. , Improvements in auditing and monitoring have taken security in health care a ...
Breaking Medicine News(10 mins):